To identify drugs that can be effectively combined with PI3Kβ inhibitor to comprehensively suppress PI3K signalling in PTEN-null tumours, Lynch et al.[68] performed a cell proliferation based drug combination screen in a panel of PTEN-null TNBC, prostate, and renal cancer cell lines. Here, PIK3CB is linked to neoplasm.